
Industry Call for Opportunities

Seeking Novel Assets and Targets in Oncology



A **mid-size biopharmaceutical company** is seeking **novel therapeutic assets and drug targets** in oncology. **Neuro-oncology** and **gastric cancer** are of highest priority, although all cancer types are welcome.

Approaches of Interest:

- Novel, druggable targets supported by a **strong biological rationale**
- Therapeutics for **solid tumors** and **hematological cancers**
- Open to modalities such as **small molecules, antibodies, bispecifics,** and **ADCs**

Out of Scope:

- Vaccines and cell therapies
- Multi-targeted tyrosine kinase inhibitors
- Drug repurposing
- Diagnostics, biomarkers, companion diagnostics, and drug delivery approaches
- Immunotherapies such as checkpoint inhibitors

Developmental Stages of Interest:

- Opportunities ranging from preclinical research through to late-stage clinical development are within scope
- *In vivo* validation (e.g. tumor models) is preferred, although highly novel targets with *in vitro* data will be considered

Submission Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. **Where relevant, please highlight the indication, target and mechanism of action related to your opportunity.** In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

Opportunities sought

- Technologies
- Research projects
- Centres of excellence
- Company profiles
- Biotech assets

Submissions

Please submit relevant, non-confidential opportunities online here

Deadline: **30th November 2026 - 11:59 pm GMT**

Have any questions?
Contact our team at campaigns@inpart.io

© 2026 All rights reserved